Learn about transformative technologies to enable antibody discovery and therapeutic development at Informa’s Antibody Technologies and Applications Digital Week, our free-to-attend webcast series. This digital week will provide cutting-edge updates on NGS-powered antibody discovery, novel bioassays, machine learning applications, case studies/lessons learned from several antibody projects and more! By attending this digital week, you will find new ideas and technology applications to help you accelerate your own antibody R&D programs.

DAY 1 – September 27, 2022



Raising the Bar for NGS-powered Antibody Discovery with Flexible Enrichment, Accurate Developability, and Interactive Phylogenetic analysis
9 AM EDT / 2 PM BST / 6 AM PDT

Integration of high-throughput sequencing data accelerates and improves discovery of novel therapeutic antibodies. However, getting from millions of sequences to a diverse set of developable antibodies with the right properties can be incredibly challenging, time-consuming, and requires significant software and computational resources. In this session, we will discuss how researchers can intuitively enrich their candidate selection using faster discovery pipelines and rich metadata information.

Learn how to:

  • Broaden your analysis beyond just the most frequently found clones and use all assay data and in-silico predictions to select the best antibody candidates
  • Track clone enrichment across panning rounds through tabular views and interactive visualizations
  • De-risk antibody development by annotating structural liabilities for thousands of sequences at once

Speaker:

Nicola Bonzanni
Co-Founder & Chief Product Officer
ENPICOM

View More Details +

Novel bioassays in Picodroplets - Accelerating Biotherapeutics Discovery and Development
11 AM EDT / 4 PM BST / 8 AM PDT

Using microfluidic devices with well-defined microchannel geometries and accurate flow control, uniform pico-litre volume droplets (picodroplets) can be generated and used as miniaturised “test tubes” for high-throughput bioassays. Cells and biomolecules encapsulated in picodroplets can be incubated, detected, sorted, and dispensed in high-throughput manner using various established microfluidic techniques. Sphere Fluidics has successfully commercialized the Cyto-Mine® instrument, which uses picodroplet technology for single-cell analysis. Cyto-Mine® provides a fully integrated workflow of single-cell encapsulation, incubation, assay, sorting, imaging, and dispensing, with capabilities of processing up to tens of millions of single cells in a working day. Confining individual cells into picodroplets enables the implementation of a range of novel bioassays and applications in biotherapeutic discovery and development, single cell genome editing and immuno-oncology.

Speaker:

Jitender Bisht
Senior Scientist
Sphere Fluidics Limited, UK

View More Details +

Mining Large Antibody Sequence Datasets for Therapeutic Antibody Discovery
12 PM EDT / 5 PM BST / 9 AM PDT

An individual’s antibody repertoire encodes information about past immune responses, and potential for disease protection. At Alchemab, we mine the antibody repertoire of individuals who are resilient to disease to discover therapeutic antibodies. Narrowing down from the vast antibody repertoire to the specific antibodies providing protection requires sophisticated computational and machine learning methods, which I will discuss in this talk.

Speaker:

Jacob Galson, Ph.D.
Head of Technology
Alchemab Therapeutics, United Kingdom

View More Details +

DAY 2 – September 28, 2022



Optimizing cell line development workflows for biotherapeutic production
9 AM EDT / 2 PM BST / 6 AM PDT  

Cell line development (CLD) is a fundamental step in developing biotherapeutic products. However, it is also time consuming and resource intensive. Considerable research has gone into developing novel techniques and instruments to derive stable cell lines more efficiently with special emphasis on assurance of monoclonality, high recovery and clone productivity. In this webinar, we will discuss strategies for setting up highly efficient CLD workflows to screen hundreds of clones with minimal hands-on time. We will share our experience on optimizing single-cell cloning and clone recovery (including plate type, culture and cloning media selection), and present upscaling strategies for the selection of high-producing clones. We will also discuss the regulatory requirements on assurance of monoclonality and demonstrate how high-quality images for NDA/IND filings can be generated. Finally, we will talk about the opportunities and challenges of laboratory automation and present a fully automated workstation for stable CLD optimized for monoclonal antibodies

Speaker:

Fernando Aprile Garcia, PhD
Chapter Lead Cell Line Development Applications
CYTENA

View More Details +

High-Throughput Assays for the Evaluation of Bispecific Antibodies following Forced Degradation
10 AM EDT / 3 PM BST / 7 AM PDT

Technical advancements in the antibody engineering has brought about greater interest in more novel antibody therapeutic design. Here we describe the development of two high throughput, no wash immunoassays along with a homogenous multiplex assay to determine the binding activity of bi-specific antibodies. We also show the novel use of a high throughput SDS-PAGE microfluidic capillary electrophoresis assay to determine the level of antibody fragmentation along with an Image-Cytometry Assay to measure bi-specific antibody potency in cell mediated cytotoxicity assays.

Speakers:

Allan Atkinson
Field Application Scientist Manager
PerkinElmer

Victor Ocasio-Ramirez, Ph.D.
Product Specialist
PerkinElmer

James Geiger, Ph.D.
Field Application Scientist
PerkinElmer

View More Details +

Design of a Chimeric ACE-2/Fc-Silent Fusion Protein with Ultrahigh Affinity and Neutralizing Capacity for SARS-CoV-2 Variants
11 AM EDT / 4 PM BST / 8 AM PDT

As the coronavirus SARS-CoV-2 continues to mutate into variants of concern (VOC), there is a growing and urgent need to develop effective antivirals to combat COVID-19. Recent data indicate that monoclonal antibodies developed early in the pandemic are no longer capable of effectively neutralizing currently active VOCs.

This talk will describe the design of a class of variant-agnostic chimeric molecules consisting of an Angiotensin Converting Enzyme-2 (ACE-2) domain mutated to retain ultrahigh affinity binding to a wide variety of SARS-CoV-2 variants, coupled to an Fc-silent immunoglobulin domain that eliminates antibody-dependent enhancement (ADE) and simultaneously extends biological half-life compared to existing mABs. It is proposed that this new class of chimeric ACE-2/mABs will constitute variant-agnostic and cost-effective prophylactics against SARS-CoV-2, particularly when administered by nasal delivery systems.

Talk attendees will learn about:

  • The development of ACE-2 Fc fusion proteins for COVID-19 prophylaxis
  • The only truly silent Fc mutations described to date
  • The engineering and expression of the ACE-2 Fc fusion proteins, done in partnership with Absolute Antibody

Speaker:

Neil Bodie
DVM, CEO
Paradigm Immunotherapeutics

View More Details +

Sequential Paratope Refinement Transforms a Polyspecific PD1 Antibody into a Truly Unique Bifunctional PD1/VEGFR2 Antagonist
12 PM EDT / 5 PM BST / 9 AM PDT

Proteomic profiling of the clinical antibody Camrelizumab revealed specific engagement with several off-target receptors, including VEGFR2. Further characterization demonstrated that interaction with VEGFR2 potently agonized receptor signaling, and this mechanism was confirmed in the clinic with the majority of dosed patients presenting with hemangiomas. Sequential paratope refinement using designer antibody libraries first removed off-target reactivities to render the antibody specific for PD1. In a second step, structure-function information gleaned from the initial study was used to flip the VEGFR2 activity from agonist to antagonist, thus generating a unique 2 in 1 PD1/VEGFR2 dual blocking antibody.

Speaker:

Orla Cunningham, Ph.D.
Chief Scientific Officer
UltraHuman Eight, United Kingdom

View More Details +

REGISTER NOW – Please select the webcast(s) you wish to attend and enter your contact details



DAY 1 – September 27, 2022

DAY 2 – September 28, 2022